SHTG Digest — Tuesday June 9, 2026

SHTG Digest — Tuesday July 14, 2026

A quiet cycle on both fronts — Part A offers three next-tier papers on FCS-gene carrier states and the ANGPTL axis rather than any top-journal blockbuster, while Part B has no genuinely new news: the period's two biggest Ionis stories (the Tryngolza sHTG label expansion and the Wainua ATTR-CM trial failure) were both already covered in the July 10 episode and have no material updates since.

SHTG Digest — Friday July 10, 2026

No top-tier journal papers cleared the bar this cycle so Part A drops down a tier to three directly relevant clinical items on hypertriglyceridemia and LPL biology, while Part B is dominated by a single but consequential Ionis story — the surprise Phase 3 failure of Wainua in ATTR-CM, which isn't a lipid-program readout but is reshaping the competitive and investor picture for Ionis and Alnylam.

SHTG Digest — Tuesday July 7, 2026

A thin cycle on both sides — the only new top-tier hit is a review on residual lipid risk beyond LDL (ANGPTL/apoC-III/FGF21 pathways get a mention), and there's no fresh industry news in the last 5 days beyond last week's Tryngolza sHTG approval, which was already covered.

SHTG Digest — Friday July 3, 2026

A quiet cycle overall — no top-tier journal papers on our core targets cleared the bar and no genuinely new industry news broke in the last five days, so this episode leans on two next-best-tier papers (an ANGPTL3-inhibitor phase 3 extension and a pediatric SHTG risk-prediction study) while the Arrowhead/Ionis/Alnylam news front stayed silent beyond what's already been covered.

SHTG Digest — Tuesday June 30, 2026

A quiet science week surfaces a novel APOC3 role in diabetic retinal angiogenesis and a diagnostic yield study for monogenic HTG, while the industry story remains Ionis' Tryngolza commercial launch into the 3.6-million-patient sHTG market following last week's FDA approval.